Stoke Therapeutics and Biogen Present Positive Zorevunersen Data for Dravet Syndrome at AES 2025 Meeting
Stoke Therapeutics and Biogen presented positive data on zorevunersen for Dravet syndrome at the AES 2025 Meeting. The data showed increased seizure-free days and improved quality of life for patients. Further safety and efficacy data are expected from the ongoing Phase 3 EMPEROR program.
Stoke Therapeutics Inc. and Biogen Inc. have announced new data presentations supporting the disease-modifying potential of zorevunersen, an investigational antisense oligonucleotide for the treatment of Dravet syndrome. The results were presented at the 2025 American Epilepsy Society (AES) Annual Meeting in Atlanta, Georgia. The presentations included findings from long-term open-label extension studies and a propensity score weighted analysis comparing zorevunersen to current standard of care, demonstrating increases in seizure-free days, improvements in quality of life, and benefits in overall clinical status for patients with Dravet syndrome. Further safety and efficacy data are anticipated from the ongoing Phase 3 EMPEROR program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stoke Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251205610875) on December 05, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
